SBIR Phase I: A new vaccine technology to engineer a potent and polarized immunity against COVID-19

这个小企业创新研究（SBIR）第一阶段项目的更广泛影响将推进一种针对新出现的病原体（例如导致COVID-19的病原体）的新疫苗输送技术。 该项目将开发一种新的工艺，可以快速制造高亲和力和精确工程免疫反应。该技术基于可注射以帮助支持免疫系统的新材料。该小企业创新研究（SBIR）第一阶段项目将使用可流动的超多孔和合成材料推进新型疫苗输送技术。这种新材料技术可以很容易地皮下或肌肉注射，以提供疫苗抗原。该材料本身作为一种持久的抗原递送载体，增加抗体产生并极化免疫系统，以最大限度地提高对所递送抗原的保护性免疫力。该项目特别关注这种新型材料的开发，以产生对新型冠状病毒（SARS-CoV-2）的多因子免疫力，以预防COVID-19。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact of this Small Business Innovation Research (SBIR) Phase I project will advance a new vaccine delivery technology against new emerging pathogens such as that causing COVID-19. This project will develop a new process that can be rapidly manufactured with high affinity and precision-engineered immune responses. The technology is based on new materials that can be injected to help support the immune system.This Small Business Innovation Research (SBIR) Phase I project will advance a novel vaccine delivery technology using flowable hyper-porous and synthetic materials. This new material technology can be easily injected subcutaneously or intramuscularly to deliver vaccine antigens. The material itself acts as a long-lasting antigen delivery vehicle, increasing antibody production and polarizing the immune system to maximize protective immunity against the delivered antigens. This project specifically focuses on development of this novel material to create multifactor immunity against the novel coronavirus (SARS-CoV-2) to protect against COVID-19.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.